Author

J. Marchica

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:metabolomics· 1

Frequent Co-Authors

B. Lee· 2 shared P. Joshi· 2 shared R. J. Perera· 2 shared A. Ray· 1 shared A. Sahoo· 1 shared C. P. Pavlovich· 1 shared D. Finlay· 1 shared F. I. A. L. Layng· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Lee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery

B. Lee, I. Mahmud, J. Marchica, P. Derezinski, F. Qi, F. Wang, P. Joshi, F. Valerio, I. Rivera, V. Patel, C. P. Pavlovich, T. Garrett, G. P. Schroth, Y. Sun, R. J. Perera

The paper identifies urine-enriched RNAs and metabolites in prostate cancer patients and normal individuals, revealing altered glutamate metabolism and TCA cycle in cancer cells.

bioRxiv · Apr 4, 2019Cancer Biology

Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma.

B. Lee, A. Sahoo, J. Marchica, J. Sawada, S. Sahoo, F. I. A. L. Layng, D. Finlay, J. Mazar, P. Joshi, M. Komatsu, K. Vuori, G. Powis, P. R. de Jong, A. Ray, R. J. Perera

This study shows MIR211 promotes melanoma growth and resistance to BRAF inhibitors by modulating the DUSP6-ERK5 axis via exosome transfer in the tumor microenvironment.

bioRxiv · Feb 13, 2019 · PreprintCancer Biology